Report of Foreign Issuer (6-k)
January 18 2017 - 8:35AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: January 2017
Commission file number: 001-36578
BIOBLAST PHARMA LTD.
(Translation of registrant's name into English)
37 Dereh Menechem Begin St., 15
th
Floor
Tel Aviv 6522042 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
This Report of Foreign
Private Issuer on Form 6-K of the Registrant consists of the press release issued by the Registrant on January 18, 2017, announcing
Phase 2a results of trehalose in patients with Spinocerebellar Ataxia Type 3 (SCA3), which is attached hereto as Exhibit 99.1.
The first five paragraphs
and the section titled “Forward Looking Statements” in the press release are incorporated by reference into the registration
statement on Form F-3 (File No. 333-206032) and the registration statements on Form S-8 (File No. 333-203114 and File No. 210459)
of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is
submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibit No.
|
99.1
|
Press
Release issued by Bioblast Pharma Ltd. on January 18, 2017, announcing Phase 2a results of trehalose in patients with SCA3.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Bioblast Pharma Ltd.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Chaime Orlev
|
|
|
|
|
Name: Chaime Orlev
Title: Chief Financial Officer, Vice President of Finance and Administration
|
|
Date: January 18, 2017
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From Apr 2024 to May 2024
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From May 2023 to May 2024